{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:38Z","timestamp":1792783358914,"version":"4.5.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Peking University-Golden Resource Tengyun Clinical Research Program","award":["TY2025010"],"award-info":[{"award-number":["TY2025010"]}],"id":[{"id":"https:\/\/ror.org\/02v51f717","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Beijing Natural Science Foundation","award":["L252203"],"award-info":[{"award-number":["L252203"]}]},{"name":"Research and Development Foundation of Peking University People\u2019s Hospital","award":["RDL2024-01"],"award-info":[{"award-number":["RDL2024-01"]}],"id":[{"id":"https:\/\/ror.org\/035adwg89","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Beijing Health Technologies Promotion Program","award":["BHTPP2022007"],"award-info":[{"award-number":["BHTPP2022007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-026-09200-3","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:11:40Z","timestamp":1790853100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking Monospecific Antibody Therapy in Chronic Rhinosinusitis with Nasal Polyps: Dual- and Multispecific Antibodies"],"prefix":"10.1007","volume":"69","author":[{"given":"Yingying","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0841-2651","authenticated-orcid":false,"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"Suppl 1","key":"9200_CR1","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1002\/alr.21695","volume":"6","author":"RR Orlandi","year":"2016","unstructured":"Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM et al (2016) International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol 6(Suppl 1):S22\u2013209. https:\/\/doi.org\/10.1002\/alr.21695","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"9200_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jaip.2016.05.004","volume":"4","author":"C Bachert","year":"2016","unstructured":"Bachert C, Akdis CA (2016) Phenotypes and Emerging Endotypes of Chronic Rhinosinusitis. J Allergy Clin Immunol Pract 4(4):621\u2013628. https:\/\/doi.org\/10.1016\/j.jaip.2016.05.004","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"9200_CR3","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.jaci.2017.09.009","volume":"140","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Gevaert E, Lou H, Wang X, Zhang L, Bachert C et al (2017) Chronic rhinosinusitis in Asia. J Allergy Clin Immunol 140(5):1230\u20131239. https:\/\/doi.org\/10.1016\/j.jaci.2017.09.009","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl S29","key":"9200_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al (2020) European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 58(Suppl S29):1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600","journal-title":"Rhinology"},{"issue":"5","key":"9200_CR5","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jaci.2022.02.016","volume":"149","author":"A Kato","year":"2022","unstructured":"Kato A, Schleimer RP, Bleier BS (2022) Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol 149(5):1491\u20131503. https:\/\/doi.org\/10.1016\/j.jaci.2022.02.016","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"9200_CR6","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1111\/all.14526","volume":"75","author":"H Hong","year":"2020","unstructured":"Hong H, Liao S, Chen F, Yang Q, Wang DY (2020) Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation. Allergy 75(11):2794\u20132804. https:\/\/doi.org\/10.1111\/all.14526","journal-title":"Allergy"},{"key":"9200_CR7","doi-asserted-by":"publisher","first-page":"1714577","DOI":"10.3389\/falgy.2025.1714577","volume":"6","author":"E Nappi","year":"2025","unstructured":"Nappi E, Marzio V, Giombi F, Costanzo G, Merli S, Nicolosi S et al (2025) Chronic rhinosinusitis with and without nasal polyps: the state-of-the-art of current treatment strategies and future developments. Front Allergy 6:1714577. https:\/\/doi.org\/10.3389\/falgy.2025.1714577","journal-title":"Front Allergy"},{"issue":"1","key":"9200_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cyto.2015.05.014","volume":"75","author":"N Gour","year":"2015","unstructured":"Gour N, Wills-Karp M (2015) IL-4 and IL-13 signaling in allergic airway disease. Cytokine 75(1):68\u201378. https:\/\/doi.org\/10.1016\/j.cyto.2015.05.014","journal-title":"Cytokine"},{"key":"9200_CR9","doi-asserted-by":"publisher","first-page":"e13444","DOI":"10.7717\/peerj.13444","volume":"10","author":"SM Nur Husna","year":"2022","unstructured":"Nur Husna SM, Md Shukri N, Mohd Ashari NS, Wong KK (2022) IL-4\/IL-13 axis as therapeutic targets in allergic rhinitis and asthma. PeerJ 10:e13444. https:\/\/doi.org\/10.7717\/peerj.13444","journal-title":"PeerJ"},{"issue":"2","key":"9200_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaci.2022.06.012","volume":"150","author":"A Shankar","year":"2022","unstructured":"Shankar A, McAlees JW, Lewkowich IP (2022) Modulation of IL-4\/IL-13 cytokine signaling in the context of allergic disease. J Allergy Clin Immunol 150(2):266\u2013276. https:\/\/doi.org\/10.1016\/j.jaci.2022.06.012","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"9200_CR11","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.4049\/jimmunol.172.7.4545","volume":"172","author":"AE Kelly-Welch","year":"2004","unstructured":"Kelly-Welch AE, Melo ME, Smith E, Ford AQ, Haudenschild C, Noben-Trauth N et al (2004) Complex role of the IL-4 receptor alpha in a murine model of airway inflammation: expression of the IL-4 receptor alpha on nonlymphoid cells of bone marrow origin contributes to severity of inflammation. J Immunol 172(7):4545\u20134555. https:\/\/doi.org\/10.4049\/jimmunol.172.7.4545","journal-title":"J Immunol"},{"issue":"10209","key":"9200_CR12","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/s0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638\u20131650. https:\/\/doi.org\/10.1016\/s0140-6736(19)31881-1","journal-title":"Lancet"},{"key":"9200_CR13","doi-asserted-by":"publisher","first-page":"102076","DOI":"10.1016\/j.eclinm.2023.102076","volume":"61","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Yan B, Shen S, Song X, Jiang Y, Shi L et al (2023) Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine 61:102076. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102076","journal-title":"EClinicalMedicine"},{"issue":"11","key":"9200_CR14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2025.12515","volume":"334","author":"S Shen","year":"2025","unstructured":"Shen S, Yan B, Wang M, Wu D, Piao Y, Tang J et al (2025) Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps: The CROWNS-2 Randomized Clinical Trial. JAMA 334(11):962\u2013972. https:\/\/doi.org\/10.1001\/jama.2025.12515","journal-title":"JAMA"},{"issue":"2","key":"9200_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jaci.2024.10.016","volume":"155","author":"SF Seys","year":"2025","unstructured":"Seys SF, Schneider S, de Kinderen J, Reitsma S, Cavaliere C, Tomazic PV et al (2025) Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR). J Allergy Clin Immunol 155(2):451\u2013460. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.016","journal-title":"J Allergy Clin Immunol"},{"key":"9200_CR16","doi-asserted-by":"publisher","unstructured":"Stilo G, Messina G, Lo Faro C, Ruta S, Frangipane S, Mariut D et al (2025) Correlation Between Smell Recovery and Nasal Polyp Score in Patients Treated with Dupilumab: A Real-Life Retrospective, Observational, Monocentric Study. J Pers Med 15(5). https:\/\/doi.org\/10.3390\/jpm15050164","DOI":"10.3390\/jpm15050164"},{"issue":"10","key":"9200_CR17","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A et al (2022) Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract 10(10):2695\u20132709. https:\/\/doi.org\/10.1016\/j.jaip.2022.05.019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"9200_CR18","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1111\/all.15844","volume":"78","author":"FS Ryser","year":"2023","unstructured":"Ryser FS, Yalamanoglu A, Valaperti A, Br\u00fchlmann C, Mauthe T, Traidl S et al (2023) Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis. Allergy 78(10):2712\u20132723. https:\/\/doi.org\/10.1111\/all.15844","journal-title":"Allergy"},{"issue":"8","key":"9200_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2183\/pjab.87.463","volume":"87","author":"K Takatsu","year":"2011","unstructured":"Takatsu K (2011) Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci 87(8):463\u2013485. https:\/\/doi.org\/10.2183\/pjab.87.463","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"9200_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cyto.2016.11.011","volume":"98","author":"T Yanagibashi","year":"2017","unstructured":"Yanagibashi T, Satoh M, Nagai Y, Koike M, Takatsu K (2017) Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5. Cytokine 98:59\u201370. https:\/\/doi.org\/10.1016\/j.cyto.2016.11.011","journal-title":"Cytokine"},{"issue":"5","key":"9200_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","volume":"180","author":"PG Woodruff","year":"2009","unstructured":"Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A et al (2009) T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 180(5):388\u2013395. https:\/\/doi.org\/10.1164\/rccm.200903-0392OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"9200_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/alr.22994","volume":"12","author":"P Gevaert","year":"2022","unstructured":"Gevaert P, Han JK, Smith SG, Sousa AR, Howarth PH, Yancey SW et al (2022) The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 12(11):1413\u20131423. https:\/\/doi.org\/10.1002\/alr.22994","journal-title":"Int Forum Allergy Rhinol"},{"issue":"6 Pt 1","key":"9200_CR23","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/s0091-6749(97)80019-x","volume":"99","author":"C Bachert","year":"1997","unstructured":"Bachert C, Wagenmann M, Hauser U, Rudack C (1997) IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 99(6 Pt 1):837\u2013842. https:\/\/doi.org\/10.1016\/s0091-6749(97)80019-x","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"9200_CR24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/s2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE et al (2021) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9(10):1141\u20131153. https:\/\/doi.org\/10.1016\/s2213-2600(21)00097-7","journal-title":"Lancet Respir Med"},{"issue":"5","key":"9200_CR25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.4193\/Rhin24.156","volume":"62","author":"S Fujieda","year":"2024","unstructured":"Fujieda S, Wang C, Yoshikawa M, Asako M, Suzaki I, Bachert C et al (2024) Mepolizumab in CRSwNP\/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia. Rhinology 62(5):576\u2013589. https:\/\/doi.org\/10.4193\/Rhin24.156","journal-title":"Rhinology"},{"issue":"6","key":"9200_CR26","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/aci.0000000000001112","volume":"25","author":"DI Bernstein","year":"2025","unstructured":"Bernstein DI (2025) Depemokimab: a new long-acting anti-IL5 treatment for severe asthma and chronic rhinosinusitis with nasal polyps. Curr Opin Allergy Clin Immunol 25(6):488\u2013492. https:\/\/doi.org\/10.1097\/aci.0000000000001112","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"10482","key":"9200_CR27","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/s0140-6736(25)00197-7","volume":"405","author":"P Gevaert","year":"2025","unstructured":"Gevaert P, Desrosiers M, Cornet M, Mullol J, De Corso E, Keles Turel N et al (2025) Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Lancet 405(10482):911\u2013926. https:\/\/doi.org\/10.1016\/s0140-6736(25)00197-7","journal-title":"Lancet"},{"issue":"4","key":"9200_CR28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","volume":"149","author":"C Bachert","year":"2022","unstructured":"Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C et al (2022) Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol 149(4):1309\u201317e12. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.030","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"9200_CR29","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1111\/bcp.16087","volume":"90","author":"C Emson","year":"2024","unstructured":"Emson C, Han JK, Hopkins C, Asimus S, Cann JA, Chain D et al (2024) Pharmacokinetics\/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial. Br J Clin Pharmacol 90(8):1952\u20131963. https:\/\/doi.org\/10.1111\/bcp.16087","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"9200_CR30","doi-asserted-by":"publisher","first-page":"E61","DOI":"10.1002\/lary.27564","volume":"129","author":"TM Laidlaw","year":"2019","unstructured":"Laidlaw TM, Prussin C, Panettieri RA, Lee S, Ferguson BJ, Adappa ND et al (2019) Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size. Laryngoscope 129(2):E61\u2013e6. https:\/\/doi.org\/10.1002\/lary.27564","journal-title":"Laryngoscope"},{"issue":"9","key":"9200_CR31","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1172\/jci85664","volume":"126","author":"C Mesnil","year":"2016","unstructured":"Mesnil C, Raulier S, Paulissen G, Xiao X, Birrell MA, Pirottin D et al (2016) Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest 126(9):3279\u20133295. https:\/\/doi.org\/10.1172\/jci85664","journal-title":"J Clin Invest"},{"issue":"6","key":"9200_CR32","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jaci.2020.02.035","volume":"145","author":"KM Buchheit","year":"2020","unstructured":"Buchheit KM, Dwyer DF, Ordovas-Montanes J, Katz HR, Lewis E, Vukovic M et al (2020) IL-5R\u03b1 marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 145(6):1574\u20131584. https:\/\/doi.org\/10.1016\/j.jaci.2020.02.035","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"9200_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/all.12054","volume":"68","author":"P Gevaert","year":"2013","unstructured":"Gevaert P, Nouri-Aria KT, Wu H, Harper CE, Takhar P, Fear DJ et al (2013) Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps. Allergy 68(1):55\u201363. https:\/\/doi.org\/10.1111\/all.12054","journal-title":"Allergy"},{"issue":"3","key":"9200_CR34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE et al (2020) Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 146(3):595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"9200_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","volume":"131","author":"P Gevaert","year":"2013","unstructured":"Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131(1):110\u20136e1. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.047","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"9200_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/1744666x.2025.2459929","volume":"21","author":"Z Jin","year":"2025","unstructured":"Jin Z, Yan B, Zhang L, Wang C (2025) Biological therapy in chronic rhinosinusitis with nasal polyps. Expert Rev Clin Immunol 21(4):473\u2013492. https:\/\/doi.org\/10.1080\/1744666x.2025.2459929","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"9200_CR37","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","volume":"149","author":"P Gevaert","year":"2022","unstructured":"Gevaert P, Saenz R, Corren J, Han JK, Mullol J, Lee SE et al (2022) Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. J Allergy Clin Immunol 149(3):957\u201365e3. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.045","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"9200_CR38","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/s2213-2600(25)00287-5","volume":"13","author":"E De Corso","year":"2025","unstructured":"De Corso E, Canonica GW, Heffler E, Springer M, Grzegorzek T, Viana M et al (2025) Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. Lancet Respir Med 13(12):1067\u20131077. https:\/\/doi.org\/10.1016\/s2213-2600(25)00287-5","journal-title":"Lancet Respir Med"},{"key":"9200_CR39","doi-asserted-by":"publisher","unstructured":"West EE, Kashyap M, Leonard WJ (2012) TSLP: A Key Regulator of Asthma Pathogenesis. Drug Discov Today Dis Mech 9(3\u20134). https:\/\/doi.org\/10.1016\/j.ddmec.2012.09.003","DOI":"10.1016\/j.ddmec.2012.09.003"},{"key":"9200_CR40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/b978-0-12-404717-4.00004-4","volume":"66","author":"SF Ziegler","year":"2013","unstructured":"Ziegler SF, Roan F, Bell BD, Stoklasek TA, Kitajima M, Han H (2013) The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol 66:129\u2013155. https:\/\/doi.org\/10.1016\/b978-0-12-404717-4.00004-4","journal-title":"Adv Pharmacol"},{"issue":"8","key":"9200_CR41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","volume":"24","author":"GM Gauvreau","year":"2020","unstructured":"Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM (2020) Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets 24(8):777\u2013792. https:\/\/doi.org\/10.1080\/14728222.2020.1783242","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"9200_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12016-025-09073-y","volume":"68","author":"F Cheng","year":"2025","unstructured":"Cheng F, Wang Y, Gao Y, Zhang C, Zhang Q, Chen J et al (2025) Current Understanding of Epithelial-Derived Alarmins in Chronic Rhinosinusitis with Nasal Polyps. Clin Rev Allergy Immunol 68(1):59. https:\/\/doi.org\/10.1007\/s12016-025-09073-y","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"9200_CR43","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","volume":"82","author":"SM Hoy","year":"2022","unstructured":"Hoy SM, Tezepelumab (2022) First Approval Drugs 82(4):461\u2013468. https:\/\/doi.org\/10.1007\/s40265-022-01679-2","journal-title":"First Approval Drugs"},{"issue":"12","key":"9200_CR44","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","volume":"392","author":"BJ Lipworth","year":"2025","unstructured":"Lipworth BJ, Han JK, Desrosiers M, Hopkins C, Lee SE, Mullol J et al (2025) Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps. N Engl J Med 392(12):1178\u20131188. https:\/\/doi.org\/10.1056\/NEJMoa2414482","journal-title":"N Engl J Med"},{"issue":"1","key":"9200_CR45","doi-asserted-by":"publisher","first-page":"8607","DOI":"10.1038\/s41467-025-63682-x","volume":"16","author":"M Xian","year":"2025","unstructured":"Xian M, Lan F, Yan B, Shen S, Liu S, Wan L et al (2025) An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial. Nat Commun 16(1):8607. https:\/\/doi.org\/10.1038\/s41467-025-63682-x","journal-title":"Nat Commun"},{"key":"9200_CR46","doi-asserted-by":"publisher","first-page":"1400696","DOI":"10.3389\/fphar.2024.1400696","volume":"15","author":"Y Fei","year":"2024","unstructured":"Fei Y, Li N, Qian W, Fan Y, Shen Y, Wang Q et al (2024) A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects. Front Pharmacol 15:1400696. https:\/\/doi.org\/10.3389\/fphar.2024.1400696","journal-title":"Front Pharmacol"},{"issue":"5","key":"9200_CR47","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jaci.2025.03.011","volume":"155","author":"R Kratchmarov","year":"2025","unstructured":"Kratchmarov R, Dharia T, Buchheit K (2025) Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 155(5):1401\u20131410. https:\/\/doi.org\/10.1016\/j.jaci.2025.03.011","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"9200_CR48","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1067\/mai.2001.112374","volume":"107","author":"C Bachert","year":"2001","unstructured":"Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P (2001) Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol 107(4):607\u2013614. https:\/\/doi.org\/10.1067\/mai.2001.112374","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"9200_CR49","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1183\/13993003.01501-2015","volume":"48","author":"P Pillai","year":"2016","unstructured":"Pillai P, Chan YC, Wu SY, Ohm-Laursen L, Thomas C, Durham SR et al (2016) Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Respir J 48(6):1593\u20131601. https:\/\/doi.org\/10.1183\/13993003.01501-2015","journal-title":"Eur Respir J"},{"key":"9200_CR50","unstructured":"Van Lancker JA, Yarnold PA, Ditto AM, Tripathi A, Conley DB, Kern RC et al (2005) Aeroallergen hypersensitivity: comparing patients with nasal polyps to those with allergic rhinitis. Allergy Asthma Proc. ;26(2):109\u2009\u2013\u200912"},{"issue":"4","key":"9200_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11882-019-0853-7","volume":"19","author":"TW Vickery","year":"2019","unstructured":"Vickery TW, Ramakrishnan VR, Suh JD (2019) The Role of Staphylococcus aureus in Patients with Chronic Sinusitis and Nasal Polyposis. Curr Allergy Asthma Rep 19(4):21. https:\/\/doi.org\/10.1007\/s11882-019-0853-7","journal-title":"Curr Allergy Asthma Rep"},{"key":"9200_CR52","doi-asserted-by":"publisher","unstructured":"Shaghayegh G, Cooksley C, Ramezanpour M, Wormald PJ, Psaltis AJ, Vreugde S, Chronic Rhinosinusitis S (2022) aureus Biofilm and Secreted Products, Inflammatory Responses, and Disease Severity. Biomedicines 10(6). https:\/\/doi.org\/10.3390\/biomedicines10061362","DOI":"10.3390\/biomedicines10061362"},{"issue":"4","key":"9200_CR53","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jaci.2016.06.066","volume":"139","author":"JB Chen","year":"2017","unstructured":"Chen JB, James LK, Davies AM, Wu YB, Rimmer J, Lund VJ et al (2017) Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 139(4):1195\u2013204e11. https:\/\/doi.org\/10.1016\/j.jaci.2016.06.066","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"9200_CR54","doi-asserted-by":"publisher","first-page":"105213","DOI":"10.1016\/j.micinf.2023.105213","volume":"25","author":"G Shaghayegh","year":"2023","unstructured":"Shaghayegh G, Cooksley C, Bouras G, Houtak G, Nepal R, Psaltis AJ et al (2023) S. aureus biofilm metabolic activity correlates positively with patients\u2019 eosinophil frequencies and disease severity in chronic rhinosinusitis. Microbes Infect 25(8):105213. https:\/\/doi.org\/10.1016\/j.micinf.2023.105213","journal-title":"Microbes Infect"},{"issue":"12","key":"9200_CR55","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1016\/j.jaip.2022.08.021","volume":"10","author":"AU Luong","year":"2022","unstructured":"Luong AU, Chua A, Alim BM, Olsson P, Javer A (2022) Allergic Fungal Rhinosinusitis: The Role and Expectations of Biologics. J Allergy Clin Immunol Pract 10(12):3156\u20133162. https:\/\/doi.org\/10.1016\/j.jaip.2022.08.021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"9200_CR56","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/all.13599","volume":"74","author":"ML Kowalski","year":"2019","unstructured":"Kowalski ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G et al (2019) Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy 74(1):28\u201339. https:\/\/doi.org\/10.1111\/all.13599","journal-title":"Allergy"},{"issue":"3","key":"9200_CR57","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP (2021) Chronic Rhinosinusitis with Nasal Polyps and Asthma. J Allergy Clin Immunol Pract 9(3):1133\u20131141. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.063","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"9200_CR58","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4193\/Rhino17.139","volume":"56","author":"T Bidder","year":"2018","unstructured":"Bidder T, Sahota J, Rennie C, Lund VJ, Robinson DS, Kariyawasam HH (2018) Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study. Rhinology 56(1):42\u201345. https:\/\/doi.org\/10.4193\/Rhino17.139","journal-title":"Rhinology"},{"issue":"7720","key":"9200_CR59","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41586-018-0449-8","volume":"560","author":"J Ordovas-Montanes","year":"2018","unstructured":"Ordovas-Montanes J, Dwyer DF, Nyquist SK, Buchheit KM, Vukovic M, Deb C et al (2018) Allergic inflammatory memory in human respiratory epithelial progenitor cells. Nature 560(7720):649\u2013654. https:\/\/doi.org\/10.1038\/s41586-018-0449-8","journal-title":"Nature"},{"key":"9200_CR60","doi-asserted-by":"publisher","unstructured":"Koo MS, Moon S, Rha MS (2024) Mucosal Inflammatory Memory in Chronic Rhinosinusitis. Cells 13(23). https:\/\/doi.org\/10.3390\/cells13231947","DOI":"10.3390\/cells13231947"},{"issue":"5","key":"9200_CR61","doi-asserted-by":"publisher","first-page":"e70282","DOI":"10.1002\/lio2.70282","volume":"10","author":"J Chiu","year":"2025","unstructured":"Chiu J, Fastenberg J, Tong C, Navetta-Modrov B, Marcus S (2025) Biologics for Chronic Rhinosinusitis With Nasal Polyposis: Current Landscape and Future Directions. Laryngoscope Investig Otolaryngol 10(5):e70282. https:\/\/doi.org\/10.1002\/lio2.70282","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"9200_CR62","doi-asserted-by":"publisher","unstructured":"Xu S, Li Y, Pan X, Zhao Y, Wu D (2025) Different Response Criteria and Response Rates for Biologic Therapy in Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review and Meta-Analysis. Ear Nose Throat J 1455613251362034. https:\/\/doi.org\/10.1177\/01455613251362034","DOI":"10.1177\/01455613251362034"},{"issue":"1","key":"9200_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-025-09130-6","volume":"69","author":"Y Zheng","year":"2026","unstructured":"Zheng Y, Liu W, Yang Y, Lu H, Wang H, Liu Z et al (2026) Baseline Blood Eosinophil Count for Identifying Superior Responders to Biologics in Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-Analysis. Clin Rev Allergy Immunol 69(1):1. https:\/\/doi.org\/10.1007\/s12016-025-09130-6","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"9200_CR64","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaci.2024.11.011","volume":"155","author":"KD Chhiba","year":"2025","unstructured":"Chhiba KD, Patel GB, Peters AT (2025) Anti-IgE therapy in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 155(1):24\u201330. https:\/\/doi.org\/10.1016\/j.jaci.2024.11.011","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"9200_CR65","doi-asserted-by":"publisher","first-page":"100529","DOI":"10.1016\/j.jacig.2025.100529","volume":"4","author":"C Bachert","year":"2025","unstructured":"Bachert C, Brusselle G, Castillo Vizuete JA, D\u00e1vila I, Laudien M, Seccia V et al (2025) Consensus from European experts on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: Results from the OverSEA Delphi study. J Allergy Clin Immunol Glob 4(4):100529. https:\/\/doi.org\/10.1016\/j.jacig.2025.100529","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"4","key":"9200_CR66","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/all.15532","volume":"78","author":"MB Soyka","year":"2023","unstructured":"Soyka MB, Ryser FS, Br\u00fchlmann C, Fehr D, D\u00fclgeroglu J, Schmid-Grendelmeier P et al (2023) Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis. Allergy 78(4):1036\u20131046. https:\/\/doi.org\/10.1111\/all.15532","journal-title":"Allergy"},{"issue":"5","key":"9200_CR67","doi-asserted-by":"publisher","first-page":"350","DOI":"10.2500\/ajra.2015.29.4231","volume":"29","author":"H Lou","year":"2015","unstructured":"Lou H, Meng Y, Piao Y, Wang C, Zhang L, Bachert C (2015) Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population. Am J Rhinol Allergy 29(5):350\u2013356. https:\/\/doi.org\/10.2500\/ajra.2015.29.4231","journal-title":"Am J Rhinol Allergy"},{"issue":"12","key":"9200_CR68","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1002\/lary.30692","volume":"133","author":"J Jin","year":"2023","unstructured":"Jin J, Guo B, Zhang W, Chen JJ, Deng YQ, Xiang R et al (2023) Predictive Value of Eosinophil Cationic Protein in Nasal Secretions in Eosinophilic Chronic Rhinosinusitis. Laryngoscope 133(12):3304\u20133312. https:\/\/doi.org\/10.1002\/lary.30692","journal-title":"Laryngoscope"},{"issue":"12","key":"9200_CR69","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/alr.23018","volume":"12","author":"G Danielides","year":"2022","unstructured":"Danielides G, Lygeros S, Kanakis M, Naxakis S (2022) Periostin as a biomarker in chronic rhinosinusitis: A contemporary systematic review. Int Forum Allergy Rhinol 12(12):1535\u20131550. https:\/\/doi.org\/10.1002\/alr.23018","journal-title":"Int Forum Allergy Rhinol"},{"key":"9200_CR70","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/tcrm.S467250","volume":"21","author":"HH Kariyawasam","year":"2025","unstructured":"Kariyawasam HH, Langan D, Rimmer J (2025) Chronic Rhinosinusitis with Nasal Polyps and Biologics: A Call for Better Data Standardisation and Presentation in Clinical Studies. Ther Clin Risk Manag 21:27\u201334. https:\/\/doi.org\/10.2147\/tcrm.S467250","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"9200_CR71","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P et al (2023) EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology 61(3):194\u2013202. https:\/\/doi.org\/10.4193\/Rhin22.489","journal-title":"Rhinology"},{"issue":"5","key":"9200_CR72","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/all.16519","volume":"80","author":"M Xian","year":"2025","unstructured":"Xian M, Yan B, Song X, Chen J, Tang J, Jiang Y et al (2025) Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps. Allergy 80(5):1208\u20131225. https:\/\/doi.org\/10.1111\/all.16519","journal-title":"Allergy"},{"key":"9200_CR73","doi-asserted-by":"publisher","unstructured":"Chinese Guidelines for Diagnosis and Treatment of Chronic Rhinosinusitis (2024) World J Otorhinolaryngol Head Neck Surg. 2026;12(1):25\u201355. https:\/\/doi.org\/10.1002\/wjo2.70031","DOI":"10.1002\/wjo2.70031"},{"key":"9200_CR74","doi-asserted-by":"publisher","unstructured":"Khosla AA, Jatwani K, Singh R, Reddy A, Jaiyesimi I, Desai A (2023) Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review. Pharmaceuticals (Basel) 16(10). https:\/\/doi.org\/10.3390\/ph16101461","DOI":"10.3390\/ph16101461"},{"key":"9200_CR75","doi-asserted-by":"publisher","first-page":"1356298","DOI":"10.3389\/fimmu.2024.1356298","volume":"15","author":"C Bachert","year":"2024","unstructured":"Bachert C, Hicks A, Gane S, Peters AT, Gevaert P, Nash S et al (2024) The interleukin-4\/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps. Front Immunol 15:1356298. https:\/\/doi.org\/10.3389\/fimmu.2024.1356298","journal-title":"Front Immunol"},{"issue":"6","key":"9200_CR76","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","volume":"9","author":"AT Peters","year":"2021","unstructured":"Peters AT, Han JK, Hellings P, Heffler E, Gevaert P, Bachert C et al (2021) Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract 9(6):2461\u201371e5. https:\/\/doi.org\/10.1016\/j.jaip.2021.01.031","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"9200_CR77","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1016\/j.jaip.2025.06.013","volume":"13","author":"JL Boechat","year":"2025","unstructured":"Boechat JL, Sousa-Pinto B, Delgado L, Silva D (2025) Targeting IL-4\/IL-13, IL-5, or IgE axes in chronic rhinosinusitis with nasal polyps with and without sinus surgery: A network meta-analysis. J Allergy Clin Immunol Pract 13(10):2861. 4.e1","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9200_CR78","doi-asserted-by":"publisher","first-page":"1700060","DOI":"10.3389\/falgy.2025.1700060","volume":"6","author":"HK Komori","year":"2025","unstructured":"Komori HK, Ortega H (2025) Potential of alarmin-targeted bispecific and combination therapies in airway disease. Front Allergy 6:1700060. https:\/\/doi.org\/10.3389\/falgy.2025.1700060","journal-title":"Front Allergy"},{"issue":"3","key":"9200_CR79","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/aci.0000000000001067","volume":"25","author":"B Abdullah","year":"2025","unstructured":"Abdullah B, Zahedi FD, Tantilipikorn P (2025) From one biologic to another: the rationale and evidence behind switching therapies in chronic rhinosinusitis. Curr Opin Allergy Clin Immunol 25(3):144\u2013150. https:\/\/doi.org\/10.1097\/aci.0000000000001067","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"9200_CR80","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/alr.23538","volume":"15","author":"M Blauwblomme","year":"2025","unstructured":"Blauwblomme M, Georgalas C, Ahmed S, Alobid I, Battaglia P, Castelnuovo P et al (2025) Expert Consensus on Surgical Management of Primary Diffuse Type 2-Dominant Chronic Rhinosinusitis. Int Forum Allergy Rhinol 15(3):303\u2013316. https:\/\/doi.org\/10.1002\/alr.23538","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"9200_CR81","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/alr.23466","volume":"15","author":"M Dorling","year":"2025","unstructured":"Dorling M, Sarafan M, Voizard B, Ammar YA, Hernaiz-Leonardo JC, Chalmers K et al (2025) Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience. Int Forum Allergy Rhinol 15(2):166\u2013173. https:\/\/doi.org\/10.1002\/alr.23466","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"9200_CR82","doi-asserted-by":"publisher","first-page":"2613548","DOI":"10.1080\/19420862.2026.2613548","volume":"18","author":"U Brinkmann","year":"2026","unstructured":"Brinkmann U, Kontermann RE (2026) The making of multispecific immunoglobulins - a clinical perspective. MAbs 18(1):2613548. https:\/\/doi.org\/10.1080\/19420862.2026.2613548","journal-title":"MAbs"},{"key":"9200_CR83","doi-asserted-by":"publisher","unstructured":"Sawant MS, Streu CN, Wu L, Tessier PM (2020) Toward Drug-Like Multispecific Antibodies by Design. Int J Mol Sci 21(20). https:\/\/doi.org\/10.3390\/ijms21207496","DOI":"10.3390\/ijms21207496"},{"issue":"3","key":"9200_CR84","doi-asserted-by":"publisher","first-page":"101349","DOI":"10.1016\/j.waojou.2026.101349","volume":"19","author":"GW Canonica","year":"2026","unstructured":"Canonica GW, Ortega-Martell JA, Villarreal-Gonz\u00e1lez RV, Ansotegui IJ, Bachert C, Bernstein J et al (2026) What is new on the horizon for the biologics world: New kids of the block - WAO state of art. World Allergy Organ J 19(3):101349. https:\/\/doi.org\/10.1016\/j.waojou.2026.101349","journal-title":"World Allergy Organ J"},{"issue":"7","key":"9200_CR85","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"ME Goebeler","year":"2024","unstructured":"Goebeler ME, Stuhler G, Bargou R (2024) Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Rev Clin Oncol 21(7):539\u2013560. https:\/\/doi.org\/10.1038\/s41571-024-00905-y","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"9200_CR86","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS et al (2024) Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med 391(16):1486\u20131498. https:\/\/doi.org\/10.1056\/NEJMoa2403614","journal-title":"N Engl J Med"},{"issue":"2","key":"9200_CR87","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","volume":"24","author":"BC Cho","year":"2023","unstructured":"Cho BC, Simi A, Sabari J, Vijayaraghavan S, Moores S, Spira A (2023) Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications. Clin Lung Cancer 24(2):89\u201397. https:\/\/doi.org\/10.1016\/j.cllc.2022.11.004","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"9200_CR88","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/s1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P et al (2022) Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23(8):1055\u20131065. https:\/\/doi.org\/10.1016\/s1470-2045(22)00335-7","journal-title":"Lancet Oncol"},{"issue":"6","key":"9200_CR89","doi-asserted-by":"publisher","first-page":"e13864","DOI":"10.1111\/cts.13864","volume":"17","author":"A Deiteren","year":"2024","unstructured":"Deiteren A, Bontinck L, Conickx G, Vigan M, Dervaux N, Gassiot M et al (2024) A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP\/anti-IL-13 NANOBODY\u00ae compound, in healthy volunteers. Clin Transl Sci 17(6):e13864. https:\/\/doi.org\/10.1111\/cts.13864","journal-title":"Clin Transl Sci"},{"key":"9200_CR90","doi-asserted-by":"publisher","unstructured":"Yu M, Chen P, Jin Y, Huang S, Jiang H, Zhou F et al (2025) A Bispecific Antibody Blocking Both TSLP and IL-4R\u03b1 for the Treatment of Allergic Inflammatory Diseases. Cells 14(22). https:\/\/doi.org\/10.3390\/cells14221747","DOI":"10.3390\/cells14221747"},{"issue":"5","key":"9200_CR91","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.anai.2025.06.020","volume":"135","author":"K Gallagher","year":"2025","unstructured":"Gallagher K, Halperin-Goldstein S, Paller AS (2025) New treatments in atopic dermatitis update. Ann Allergy Asthma Immunol 135(5):498\u2013510e10. https:\/\/doi.org\/10.1016\/j.anai.2025.06.020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9200_CR92","doi-asserted-by":"publisher","unstructured":"Deiteren A, Krupka E, Bontinck L, Imberdis K, Conickx G, Bas S et al (2025) A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. Eur Respir J 65(4). https:\/\/doi.org\/10.1183\/13993003.01461-2024","DOI":"10.1183\/13993003.01461-2024"},{"key":"9200_CR93","unstructured":"sanofi: Press Release (2026) Sanofi\u2019s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2026\/-04-07-05-00-00-3268809 (2026-4-7). Accessed"},{"key":"9200_CR94","doi-asserted-by":"publisher","unstructured":"Jiang J, Zhai T, Chen Y, Dai S, Zhou S, Zhang Z et al BBT002, a tetravalent bispecific antibody targeting human IL-4R\u03b1 and IL-5, demonstrated synergistic efficacy in vitro and in a porcine pancreatic elastase (PPE)-induced COPD mouse model. Eur Respir J. 66(suppl 69):OA6528. https:\/\/doi.org\/10.1183\/13993003.congress-2025.OA6528","DOI":"10.1183\/13993003.congress-2025.OA6528"},{"key":"9200_CR95","unstructured":"Pfizer (2026) Pfizer\u2019s Phase 2 Study of Trispecific Antibody Positive in Moderate-to-Severe Atopic Dermatitis. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-phase-2-study-trispecific-antibody-positive? Accessed"},{"key":"9200_CR96","doi-asserted-by":"publisher","first-page":"105037","DOI":"10.1016\/j.critrevonc.2025.105037","volume":"217","author":"OJ Okpasuo","year":"2026","unstructured":"Okpasuo OJ, Olaoba OT, Bokolo P, Aleke AS, Dare A, Adelusi TI et al (2026) The evolving landscape of antibody-based cancer therapies: From monospecific to multi-specific and beyond. Crit Rev Oncol Hematol 217:105037. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105037","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"9200_CR97","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41571-024-00946-3","volume":"21","author":"CAJ van Winkel","year":"2024","unstructured":"van Winkel CAJ, Pierik FR, Brouwers AH, de Groot DJA, de Vries EGE, Lub-de Hooge MN (2024) Molecular imaging supports the development of multispecific cancer antibodies. Nat Rev Clin Oncol 21(12):852\u2013866. https:\/\/doi.org\/10.1038\/s41571-024-00946-3","journal-title":"Nat Rev Clin Oncol"},{"key":"9200_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/alr.70125","author":"NJ Campion","year":"2026","unstructured":"Campion NJ, Petsiou DP, Fally FC, Berbalk K, Melamed NF, Tu A et al (2026) Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes. Int Forum Allergy Rhinol. https:\/\/doi.org\/10.1002\/alr.70125","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"9200_CR99","doi-asserted-by":"publisher","first-page":"23051","DOI":"10.1038\/s41598-025-07658-3","volume":"15","author":"K Walla","year":"2025","unstructured":"Walla K, Habenbacher M, Kay J, Walrave L, G\u00fcnzl P, Tomazic PV et al (2025) Current diagnostic and therapeutic management of chronic rhinosinusitis with nasal polyps in Austria: insights and unmet needs from a nationwide survey. Sci Rep 15(1):23051. https:\/\/doi.org\/10.1038\/s41598-025-07658-3","journal-title":"Sci Rep"},{"key":"9200_CR100","doi-asserted-by":"publisher","unstructured":"Piazzetta GL, Lobello N, Di Agostino S, Coscarella I, Pelaia C, Di Vito A et al (2026) Mucosal Remodeling in Chronic Rhinosinusitis with Nasal Polyps: The Role of Innate Lymphoid Cells and Reprogramming Under IL-4R\u03b1 Blockade. Int J Mol Sci 27(4). https:\/\/doi.org\/10.3390\/ijms27041992","DOI":"10.3390\/ijms27041992"},{"key":"9200_CR101","doi-asserted-by":"publisher","unstructured":"Lee K, Tai J, Lee SH, Kim TH (2021) Advances in the Knowledge of the Underlying Airway Remodeling Mechanisms in Chronic Rhinosinusitis Based on the Endotypes: A Review. Int J Mol Sci 22(2). https:\/\/doi.org\/10.3390\/ijms22020910","DOI":"10.3390\/ijms22020910"},{"key":"9200_CR102","doi-asserted-by":"publisher","first-page":"1581153","DOI":"10.3389\/fimmu.2025.1581153","volume":"16","author":"J Grudzinska-Goebel","year":"2025","unstructured":"Grudzinska-Goebel J, Benstein K, Bloem K, Cowan KJ, Gorovits B, Jadhav M et al (2025) Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform. Front Immunol 16:1581153. https:\/\/doi.org\/10.3389\/fimmu.2025.1581153","journal-title":"Front Immunol"},{"key":"9200_CR103","doi-asserted-by":"publisher","unstructured":"Chen YS, Feng CY, Su SH, Wang YH, Yang TH, Lin CF (2025) Recurrence of Chronic Rhinosinusitis with Nasal Polyps After Surgery: Risk Factors, Predictive Models, and Treatment Approaches with a Focus on Western and Asian Differences. Med (Kaunas) 61(9). https:\/\/doi.org\/10.3390\/medicina61091620","DOI":"10.3390\/medicina61091620"},{"issue":"1","key":"9200_CR104","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11882-025-01243-4","volume":"26","author":"MF Armstrong","year":"2026","unstructured":"Armstrong MF, Senior BA (2026) Biologics in Chronic Rhinosinusitis with Nasal Polyps: The Otolaryngologist\u2019s Perspective. Curr Allergy Asthma Rep 26(1):4. https:\/\/doi.org\/10.1007\/s11882-025-01243-4","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"9200_CR105","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11882-025-01246-1","volume":"26","author":"E De Corso","year":"2026","unstructured":"De Corso E, Canevari FRM, Caminati M, Pipolo C, Heffler E, Lazzeroni M et al (2026) Chronic Rhinosinusitis Optimisation of Nasal Outcomes and Scores (CHRONOS): An Italian Delphi Consensus on Long-Term Management with Biologics. Curr Allergy Asthma Rep 26(1):3. https:\/\/doi.org\/10.1007\/s11882-025-01246-1","journal-title":"Curr Allergy Asthma Rep"},{"issue":"4","key":"9200_CR106","doi-asserted-by":"publisher","first-page":"101633","DOI":"10.1016\/j.bjorl.2025.101633","volume":"91","author":"H Chen","year":"2025","unstructured":"Chen H, Wang L, Zhang J, Yan X, Yu L, Jiang Y (2025) Long-term efficacy and safety of different biologics in treatment of chronic rhinosinusitis with nasal polyps: A network meta-analysis. Braz J Otorhinolaryngol 91(4):101633. https:\/\/doi.org\/10.1016\/j.bjorl.2025.101633","journal-title":"Braz J Otorhinolaryngol"},{"issue":"5","key":"9200_CR107","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/all.16499","volume":"80","author":"S Cai","year":"2025","unstructured":"Cai S, Xu S, Zhao Y, Zhang L (2025) Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta-Analysis of Real-World Evidence. Allergy 80(5):1256\u20131270. https:\/\/doi.org\/10.1111\/all.16499","journal-title":"Allergy"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09200-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-026-09200-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09200-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:11:44Z","timestamp":1790853104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-026-09200-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9200"],"URL":"https:\/\/doi.org\/10.1007\/s12016-026-09200-3","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"1 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article is a narrative review of previously published literature and does not involve human participants, human data, or animal experiments.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"81"}}